Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2018

View Archived Issues

SRC-3 shushes stem cells

Misfolded tau proteins differ by tauopathy

Novartis describes profile of promising BTK inhibitor LOU-064

BAY-1101042, a potent NO- and heme-independent sGC activator suitable for oral dosing

Selective nonlethal mechanism-based inhibitors of gut microbial TMAO reduce thrombosis potential

Medications for alcohol or opioid use disorders may reduce suicidal behavior and criminality

New phase I trial evaluates Inovio's GLS-6150 to prevent hepatitis C

OPKO Health announces initiation of phase II study of Rayaldee in dialysis patients

Additional positive data presented from phase IIa study of NasoVAX intranasal influenza vaccine

Boehringer Ingelheim and Tsinghua University to develop novel therapies against infectious diseases

Nerlynx approved in Europe as extended adjuvant therapy of HER2-positive early-stage breast cancer

Positive results reported across multiple endpoints in ZENITH-1 trial of oral BCX-7353

Ossianix to use BBB delivery technology with agents from Novo Nordisk

Development of a new PDE9A inhibitor for the treatment of CNS diseases

National Institute of Pharmaceutical R&D divulges BTK ihibitors

Palobiofarma and Novartis patent adenosine A2A receptor antagonists

FDA grants IND clearance for phase II/III study of LYS-SAF-302 for MPS IIIA

Galderma Research & Development discloses RORC inverse agonists

Oryzon Genomics identifies new lysine-specific demethylase inhibitors

Tesaro advances JASPER study of Zejula in NSCLC

Turnstone Biologics and La Jolla Institute collaborate to develop new cancer immunotherapies

Elunate approved in China for colorectal cancer

Pieris initiates phase I trial of PRS-343 plus atezolizumab in HER2-positive solid tumors

New PARP-1 inhibitor presented for cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...